IP Library Granted Patent US 6,894,149
Granted Patent B2
US 6,894,149 · App. 10/268,883 · Granted May 17, 2005

Anti-HLA-DA antibodies and the methods of using thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,894,149
App. No.
10/268,883
Granted
May 17, 2005
Kind
B2
Abstract

This invention provides anti-HLA-DR antibodies and the methods of use thereof for the treatment of leukemia or lymphomas, or solid tumors such as ovarian cancer or melanoma.

Claims (13)

1. An isolated antibody that binds to HLA-DR, wherein said antibody comprises a heavy chain having an amino acid sequence of SEQ ID NO: 3.

2. The antibody according to claim 1 , wherein said antibody comprises a light chain having an amino acid sequence of SEQ ID NO: 6.

3. The antibody according to claim 2 , wherein said antibody is an IgG1 antibody.

4. The antibody according to claim 2 , wherein said antibody comprises a kappa light chain.

5. An isolated antibody that binds to HLA-DR, wherein said antibody comprises a heavy chain having an amino acid sequence of SEQ ID NO: 9.

6. The antibody according to claim 5 , wherein said antibody comprises a light chain having an amino acid sequence of SEQ ID NO: 12.

7. The antibody according to claim 1 , wherein said antibody is an antibody tetramer, Fab fragment, (Fab′) 2 , or Fv.

8. The antibody according to claim 5 , wherein said antibody is an antibody tetramer, Fab fragment, (Fab′) 2 , or Fv.

9. An antibody conjugate comprising the antibody according to claim 1 .

10. An antibody conjugate comprising the antibody according to claim 5 .

11. The antibody conjugate according to claim 9 , wherein said antibody is conjugated with a cytotoxin.

12. A pharmaceutical composition comprising the antibody according to claim 1 and a pharmaceutical carrier.

13. A pharmaceutical composition comprising the antibody according to claim 5 and a pharmaceutical carrier.

Assignments (5)
CHANGE OF NAME Recorded Aug 12, 2015
From: ABBOTT BIOTHERAPEUTICS CORP
To: ABBVIE BIOTHERAPEUTICS INC
Reel/Frame 036308/0865 →
CHANGE OF NAME Recorded Dec 7, 2010
From: FACET BIOTECH CORPORATION
To: ABBOTT BIOTHERAPEUTICS CORP.
Reel/Frame 025445/0807 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 023649/0752 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2006
From: MCPHATE GREEN, JENNIFER; TSO, J. YUN
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 017649/0446 →
CHANGE OF NAME Recorded May 22, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017655/0436 →